Paul Bisaro
CIK 1237253 · Executive Chairman · last filed 2026-07-17
Paul Bisaro is an Executive Chairman who has filed 133 SEC Form 4 insider transactions across 11 companies since 2007. Across all open-market trades the lifetime net is −$38.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.5M across reported positions. 19 SEC filings were submitted jointly with Actavis plc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BRL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PARSIPPANY, NJ 07054
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MYGN | Director | 157,142 | $6.04 | $948.4K | $27.6K | 6 | 2026-06-05 |
| ZTS | Director | 27,862 | $79.89 | $2.23M | $151.8K | 24 | 2026-05-13 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 71,131 | $0.34 | $24.2K | $42.3K | 5 | 2023-06-29 |
| TXMD | Director | 5,922 | $1.70 | $10.1K | $96.5K | 7 | 2022-10-03 |
| AMRX | Executive Chairman | 29,454 | $20.20 | $595.0K | $203.5K | 4 | 2019-05-09 |
| Allergan plc (AGN) Delisted | Director | 383,729 | — | — | -$16.97M | 13 | 2018-05-04 |
| ZBH | Director | — | $106.05 | — | $0 | 15 | 2017-04-04 |
| Impax Laboratories, LLC (IPXL) Delisted | President and CEO | — | — | — | $0 | 1 | 2017-03-29 |
| ACT | Exec Chairman | 422,531 | $46.65 | $19.71M | $0 | 2 | 2015-03-09 |
| Actavis, Inc. (WPI) Delisted | President & CEO | 307,339 | — | — | $0 | 12 | 2012-03-16 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | 133,078 | — | — | -$22.00M | 25 | 2007-10-24 |
Recent Filings
133 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | — | Grant (A) | — | $0 | |
| 2026-06-05 | MYGN | Grant (A) | +59,701 | $0 | EDGAR |
| 2026-06-04 | — | Mixed | +2,066 | $0 | |
| 2026-05-14 | MYGN | Buy (P) | +7,500 | $27.6K | EDGAR |
| 2026-05-13 | ZTS | Buy (P) | +2,000 | $151.8K | EDGAR |
| 2026-02-25 | — | Grant (A) | — | $0 | |
| 2026-02-23 | ZTS | Exer (M) | +1,619 | $0 | EDGAR |
| 2026-02-19 | ZTS | Grant (A) | — | $0 | EDGAR |
| 2026-01-05 | — | Mixed | +2,160 | $0 | |
| 2025-08-18 | — | Grant (A) | — | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.